All Episodes

409: Predicting biotech clinical trials & a new Alzheimer's drug controversy

408: Whistleblower takes on health insurance and FDA commissioner candidates

407: The mysterious case of Eli Lilly's obesity drug

406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

405: An obesity drug deep-dive, and peptides move mainstream

404: What RevMed's pancreatic cancer drug meant for one patient

403: Biotech exec Jeremy Levin on the industry's strategic turning point

402: Guarding biotech from China and big bets in longevity

401: Makary’s departure and Cassidy’s tenuous Senate seat

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

399: Hair-raising trial results, and Servier’s M&A wishlist

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

396: A new trick for old science, and biotech VCs' scrambled playbook

395: Biotech investors' plea to Trump, and a busy M&A week

394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy

393: A conversation with the 'godfather' of biotech

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

391: Breaching the IBD efficacy ceiling, and sham surgeries

390: FDA turmoil, election intrigue, AI, and more

389: Hims' Super Bowl fallout, and the FDA reverses course

388: The FDA's refusal to review Moderna's mRNA flu vaccine

387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

From Drug Story: Lipitor and Heart Disease

386: The high stakes for Huntington's patients

385: A measles outbreak and hospitals' financial troubles

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

383: JPM to bring more deals and happy CEOs

382: Biotech's year in review

381: The future of American science and a dispatch from ASH

380: A new top drug regulator and the future of psychedelics

379: How Mark Cuban plans to ‘f— up’ health care

378: Merck's heart disease win and the FDA's new drug regulator

377: Melodrama at the FDA and the Pfizer-Novo bidding war

376: BridgeBio’s great week and Moderna’s unraveling

375: Startups push the FDA and biotech booms in North Carolina

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

373: Party in biotech land and AstraZeneca’s miscalculation

372: A pharma C-suite shakeup and Trump's deal with Pfizer

371: A gene therapy success in Huntington's and Trump's autism announcement

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

358: FDA's gene therapy turmoil, and an alternative model for funding research

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

354: Uncertainty in CRISPR world and the start of more M&A

353: Trump's drug-pricing plan and a potential Theranos 2.0

352: A firebrand takes oversight of vaccines, gene therapies

351: It's gonna be May (in biotech)

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

348: Cuts, ousters and drama at the FDA

347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival

346: Zealand's obesity strategy and Immunovant's curious development plan

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

344: Trump's FDA commissioner nominee takes the hot seat

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

342: FDA cuts, zombie biotechs, and too much weight loss?

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

From Tradeoffs: Race to the Bottom

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

From "Say More": What Happens When AI Decides Your Medical Coverage

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

318: Drug pricing drops & psychedelics under fire

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

313: Biotech layoffs, founder-focused VC, & a big pharma exit

312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

308: An ASCO preview & another Duchenne trial failure

307: More tumult at BIO & coercive care for sickle cell patients

306: Live! From the STAT Breakthrough Summit West

305: Everything you need to know about H5N1 bird flu

304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

302: Vertex's big deal, biotech's red numbers, & an industry history lesson

301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

299: Live! From the STAT Breakthrough Summit East

298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

297: VC turmoil, GLP-1 competition, & the war on recovery

296: Legal insider trading, booming biotech stocks, & the next GLP-1

295: Humira’s legacy, CEO symbolism, and genomic surgery

294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

293: AI in medicine, detangling hype, and Icelandic DNA

292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

291: The plight of the VC, Gilead's latest setback, & more M&A

290: Biotech layoffs, slumping stocks, and a 2024 preview

289: Live! From #JPM24

287: 2023 in review, CEO report cards, and a look at the year ahead

286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

285: CRISPR history, biotech struggles, & a big week for deals

284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

283: A CRISPR milestone, algorithms amok, & biotech mixology

From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

279: Live from the 2023 STAT Summit

278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

275: A thorny ALS debate at the FDA, and the promise of artificial wombs

274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

272: Vivek's star turn, leaky drug data, & biotech as family business

271: Racing for gene therapy, a pioneering approval, & startups in the lurch

270: Your guide to Wegovy’s blockbuster heart study

269: Biotech layoffs, eye drug drama, & gene therapy milestones

268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

264: Messy PBM conflicts, debatable vaccines, & the future of flu season

263: Biogen's messy board, Laronde's data problem, & the downside of a boom

262: Merck v. USA, the best of ASCO, and Leqembi at the FDA

261: Fake medical devices, real cancer drugs, & curious Ozempic effects

260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters

254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster

250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

247: Vertex vs. insurers, Moderna's future, & biotech's long winter

246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid

245: The return of bird flu and the effects of pandemic fatigue

244: Pharma blockbusters, pandemic policy, & legal chicanery

243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection

242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score

241: #JPM23 in review, the year ahead, & the merits of Miami

240: #JPM23, the future of Alzheimer's, & rising Covid variants

239: 2022 in review, CEO indictments, & the year ahead

238: Leaky health data, ASH22, & what it takes to get booed by your peers

237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

235: LIVE from the STAT Summit

234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

233: How the biotech revolution could come apart at the seams

232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market

230: BIO's messy transition, mRNA's future, & Biogen's next CEO

229: Nobels for science, biotech dealmaking, & a friendly FTC

228: A surprise success in Alzheimer's and how FDA history seeded modern controversy

227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0

226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO

222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment

221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data

218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search

217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'

216: VC malaise, FDA confusion, & yet another Alzheimer's debate

215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

214: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict

213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

211: Biotech's catch-22, a $100 genome, & dealing with monkeypox

210: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges

Episode 209: Mysterious infections, dwindling Covid funds, & Shkreli out of prison

Episode 208: A CEO's arrest, Pfizer's big deal, & Covid on the rise

Episode 207: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner

Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum

Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices

Episode 204: Leana Wen on the pandemic's new normal and whether Twitter is real life

Episode 203: What's next for Roche, a debate over second boosters, & Vertex's recent success

Introducing: Color Code

Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO

Episode 201: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas

Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV

Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR

Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron

Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay

Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic

Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids

Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron

Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project

Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict

Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron

Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving

Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga

Episode 184: Vaccines for kids, inside Operation Warp Speed, & a big biotech resignation

Episode 183: Greg Zuckerman on the vaccine race, plus Biogen's troubled launch

Episode 182: The FDA star search, more booster debates, & the future of mRNA

Episode 181: Brent Hodge on filming Shkreli, the next NIH director, and a looming FDA deadline

Episode 180: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest

Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout

Episode 178: Futuristic prosthetics, a treatment for ALS, & intrigue at the Holmes trial

Episode 177: Bijan Salehizadeh on Covid tests, plus Verily's moment of truth

Episode 176: Elizabeth Holmes on trial, FDA in disarray, & the quest for Covid antivirals

Episode 175: Dorit Reiss on vaccine mandates, plus biotech's messy summer

Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading

Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms

Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's

Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen

Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying

Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist

Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer

Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,

Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer

Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade

Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug

Episode 163: Marilynn Marchione on covering the CRISPR babies scandal

Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA

Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity

Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit

Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging

Episode 158: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt

Episode 157: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside

Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19

Episode 155: AstraZeneca's vaccine woes, compassionate use, & giving out Covid vaccines

Episode 154: Eleanor Fox on Illumina’s FTC headache, plus Talkspace’s experiment

Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer

Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase

Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise

Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future

Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks

Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring

Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation

Episode 144: Remembering STAT's Sharon Begley

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy

Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021

Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution

Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021

Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered

Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary

Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old

Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5

Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's

Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials

Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos

Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting

Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest

Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round

Episode 128: AstraZeneca’s Covid-19 vaccine, coronavirus politics, & STAT’s Health Tech Summit

Episode 127: Eric Topol on Stephen Hahn, plus Covid-19 vaccine timelines, & the 2000th First Opinion

Episode 126: The FDA's chaotic week, Trump's effect on science, and Musk's big reveal

Episode 125: Shocking FDA rejections, a longevity science setback & Derek Lowe on Covid-19 vaccines

Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies

Episode 123: Steven Salzberg's Twitter debate, a health tech mega-deal & Covid-19 vaccine prices

Episode 122: Gary Washburn on the NBA bubble, plus a DIY coronavirus vaccine, & behind VC numbers

Episode 121: Kate Bingham on vaccine data, Meg Tirrell on covering Covid-19, & a DNA detective story

Episode 120: Moderna's vaccine data, saving the U.S. pandemic response & systemic racism in medicine

Episode 119: Trump's FDA pressure, a microcosm of the pandemic, and squabbling over a vaccine

Episode 118: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life

Episode 117: Covid-19’s U.S. surge, GSK’s mystery whistleblower, and cancer care under coronavirus

Episode 116: Ezekiel Emanuel on vaccine politics & Tshaka Cunningham on diversifying genetic testing

Episode 115: The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19

Episode 114: The killing of George Floyd, the drug industry's response, and what comes next

Episode 113: Life after a coronavirus vaccine, virtual ASCO, and remembering Larry Kramer

Episode 112: Moderna's scant coronavirus data and the plight of the day trader

Episode 111: Covid-19 in the White House, a Parkinson’s experiment & public health lessons from porn

Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York

Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day

Episode 108: A vaccine official is ousted, how to use ventilators, & the fate of the JPM conference

Episode 107: Covid-19 disrupts D.C., how not to be boring on Zoom, and the trial of Elizabeth Holmes

Episode 106: Privacy in a pandemic, biopharma's big opportunity, and Shkreli's plea for a break

Episode 105: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA

Episode 104: Fauci's star turn, the latest on coronavirus, and an under-the-radar Alzheimer's drug

Episode 103: Trump's coronavirus pivot, life inside the ICU & drug development in a pandemic

Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas

Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China

Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back

Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review

Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy

Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore

Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern

Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos

Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap

Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga

Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease

Episode 91: CAR-T's future, an alarming cancer trend & Chris Garabedian on Sarepta's FDA legacy

Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep

Episode 89: Warren's awkward home front, a dwarfism drug, and the sound of STAT Summit

Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter

Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday

Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation'

Episode 85: Every angle on Biogen's shocking Alzheimer's news

Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from

Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology

Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood

Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing

Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter

Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure

Episode 78: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

Episode 77: Purdue, J&J, and a week of big opioid crisis news

Episode 76: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study

Episode 74: Novartis and the no good, very bad week

Episode 73: Canadian pills, corporate jets, & racists with spit kits

Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health

Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety

Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech

Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life

Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world

Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party

Episode 65: A special episode from the halls of the ASCO meeting

Episode 64: Feuding professors, failing businesses, and journalism 101

Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer

Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials

Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print

Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound

Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges

Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores

Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen

Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation

Episode 51: CEOs at the Senate, merger mania, and sleuthing startups

Episode 50: A big scoop on opioid marketing

Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill

Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH

Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?

Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns

Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics

Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics

Episode 43: A people's history of J.P. Morgan

Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests

Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history

Episode 38: Your guide to the #CRISPRbabies controversy

Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug

Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence

Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma

Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy

Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn

Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round

Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics

Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping

Episode 27: Live from Boston!

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer

Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags

Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T

Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers

Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest

Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data

Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season

Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'

Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts

Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China

Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype

Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT

Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO

Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?

Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen

Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes

Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?

Episode #9 - Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics

Episode #8 - Megamergers, migraines, and biotech's Four Horsemen

Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism

Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR

Episode #5 - The FDA's cold shoulder, the latest CAR-T contender, and BuzzFeed's scoop on Grindr

Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card

Episode #3 - A gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?

Episode #2 - Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies

Episode #1 - Shkreli's sentence, biotech froth, and a blood party

Coming soon: "The Readout LOUD"